IRIS
PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.774
EU - Europa 1.755
AS - Asia 456
AF - Africa 369
OC - Oceania 10
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.372
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.650
IT - Italia 627
IE - Irlanda 416
CN - Cina 363
UA - Ucraina 272
CI - Costa d'Avorio 242
DE - Germania 129
CA - Canada 123
SN - Senegal 120
RU - Federazione Russa 108
FR - Francia 43
SE - Svezia 32
IN - India 27
BE - Belgio 22
GB - Regno Unito 22
ES - Italia 18
SG - Singapore 13
NL - Olanda 11
VN - Vietnam 11
AU - Australia 10
CH - Svizzera 10
AT - Austria 9
IR - Iran 9
GR - Grecia 8
JP - Giappone 8
FI - Finlandia 7
HU - Ungheria 7
PL - Polonia 5
ID - Indonesia 4
LB - Libano 4
NG - Nigeria 4
PK - Pakistan 4
UZ - Uzbekistan 4
TR - Turchia 3
BG - Bulgaria 2
BR - Brasile 2
CL - Cile 2
CZ - Repubblica Ceca 2
EG - Egitto 2
HK - Hong Kong 2
IL - Israele 2
AE - Emirati Arabi Uniti 1
CO - Colombia 1
DK - Danimarca 1
EC - Ecuador 1
EU - Europa 1
IM - Isola di Man 1
KZ - Kazakistan 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
SL - Sierra Leone 1
Totale 5.372
Salva come PNG Salva come JPEG
Città #
Chandler 606
Houston 471
Dublin 413
Jacksonville 285
Abidjan 242
Catania 165
Ashburn 161
Dakar 120
Nanjing 117
Cambridge 112
Andover 111
Lawrence 111
Toronto 94
Bremen 62
Wilmington 58
Boardman 52
Des Moines 51
San Mateo 47
Rome 41
Grafing 36
Shenyang 35
Nanchang 34
Saint Petersburg 33
Jiaxing 26
Ottawa 25
Changsha 23
Brussels 21
Hebei 21
Tianjin 19
Pune 17
Falls Church 15
Messina 15
Moscow 13
Beijing 12
Dong Ket 11
Ningbo 10
Norwalk 10
Augusta 9
Jinan 9
Madrid 9
Ardabil 8
Leawood 8
Milan 8
New York 8
San Francisco 8
San Giovanni la Punta 8
Budapest 7
Melbourne 7
Monmouth Junction 7
Paris 7
Seattle 7
Tappahannock 7
Washington 7
Den Haag 6
Fukuoka 6
Lentini 6
Rimini 6
San Gregorio di Catania 6
Vittoria 6
Bari 5
Bologna 5
Dearborn 5
Froges 5
Heidelberg 5
Kunming 5
Marseille 5
Terrassa 5
Villafranca Tirrena 5
Abuja 4
Civitavecchia 4
Fremont 4
Gravina di Catania 4
Groningen 4
Guangzhou 4
Helsinki 4
Liberty Lake 4
Los Angeles 4
Misterbianco 4
Naples 4
Valencia 4
Benevento 3
Camerino 3
Chioggia 3
Ghisalba 3
Haikou 3
Lahore 3
Lappeenranta 3
Lercara Friddi 3
Mascalucia 3
Modica 3
Pace 3
Ponzano Romano 3
Pozzo Di Gotto 3
Randazzo 3
Reggio Calabria 3
Riposto 3
Scicli 3
Trieste 3
Zhengzhou 3
Agrate Brianza 2
Totale 4.007
Salva come PNG Salva come JPEG
Nome #
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 353
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 172
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 107
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 99
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 98
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 78
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 73
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 72
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 72
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 67
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 65
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 64
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 61
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 61
Intercellular communication and ion channels in neuropathic pain chronicization 61
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 60
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 60
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 58
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 58
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 57
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 54
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 53
MOR/DOR targeting: an useful strategy in pain management 53
SYNTHESIS OF (+)-(1'R,2'S) AND (1'S,2'R)-6,11-DIMETHYL-1,2,3,4,5,6-HEXAHYDRO-3-[[2'-(ALKOXYCARBONYL)-2'-PHENYLCYCLOPROPYL]METHYL]-2,6-METHANO-3-BENZAZOCIN-8-OL. COMPARISON OF THE AFFINITIES FOR SIGMA 1 AND OPIOID RECEPTORS WITHIN THE DIASTEREOISOMERIC MPCB AND CCB 52
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 51
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 51
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 51
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 50
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 50
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 50
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 50
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 49
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 49
Analgesici oppioidi: nuove opportunità nella terapia del dolore 49
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 49
Multitarget opioid ligands in pain relief: New players in an old game 48
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 48
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 48
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 48
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 48
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 48
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 47
New developments in opioid receptors ligands 47
Development of new benzomorphan LP1 analogues 47
Bivalent opioid-peptides synthesized from mu-selective monomers display preferential selectivity for delta-receptors 47
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 47
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 46
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 46
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 45
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 44
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 44
MOR/DOR targeting: an useful strategy in pain management 44
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 44
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 44
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 43
Specific kappa opioid receptor agonists 42
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 41
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 41
Progress in the development of more effective and safer analgesics for pain management 41
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 40
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 40
In-vitro evaluation of a new benzomorphan-based ligand 40
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 40
In vitro evaluation of new benzomorphan-based ligands 39
Modulation of opioid receptor profile of LP1 analogues through the introduction of different N-substituents 39
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 38
Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity. 38
Pain management: new long-acting opioid ligands 38
New bifunctional antioxidant/σ1 agonist ligands: preliminary chemico-physical and biological evaluation 37
Synthesis and pharmacological properties of N-thienyl alkylenediamines 37
Glycopeptide- and carbohydrate-based synthetic vaccines for cancer immunotherapy 37
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 37
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 37
Opioid multiple ligands 36
Resveratrol-loaded lipid nanocarriers: Correlation between in vitro occlusion factor and in vivo skin hydrating effect 36
Synthesis of substituted pyrimidines, pyrazole[3,4-d]pyrimidines and imidazo[4,5-d]pyrimidines and evaluation of their antifungal activity 36
From plant to bench: natural products as source for analgesic drug development. 36
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 36
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 35
INTERACTION OF A NEW ANALGESIC AGENT, LP1, WITH THE BIOMEMBRANE MODELS: CALORIMETRIC STUDY 35
In vitro evaluation of new benzomorphan-based ligands 35
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 35
Development of new benzomorphan LP1 analogues 35
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 35
Synthesis and structure-activity relationships of (-)-cis-N-Normetazocine-based LP1 derivatives. MOR/DOR targeting mediates neuropathic pain amelioration in chronic constriction injured rats. 35
MOR/DOR targeting mediates neuropathic pain amelioration in chronic constriction injured rats. 35
Idebenone: Novel strategies to improve its systemic and local efficacy 34
The benzomorphan-based LP1 is a central-acting multitarget opioid ligand for chronic pain treatment. 33
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 33
Evaluation of N-substitution in 6,7-benzomorphan compounds 32
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 31
The benzomorphan-based LP1 ligand is a suitable MOP/DOP receptors agonist for chronic pain treatment 31
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 31
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 31
PEPTIDOMIMETICS OF THE KAPPA-OPIOID RECEPTOR. A HYBRID MPCB /PEPTIDE LIGAND (MPCB-RRI) BINDS KAPPA CLONED RECEPTOR WITH NANOMOLAR AFFINITY 31
In Vitro Evaluation of Sunscreen Safety: Effects of the Vehicle and Repeated Applications on Skin Permeation from Topical Formulations 31
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 29
New (+)- and (–)-1-phenyl-3-azabicyclo[3.1.0]hexanes as probes for sigma receptors 29
Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties 29
The blockade of NOP receptor in the vIPAG reduces the development of tolerance to opioid-induced antinociception in rats 28
Totale 5.075
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.703
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.703
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019185 0 0 0 0 0 0 0 0 0 5 24 156
2019/2020888 255 72 118 76 112 19 48 16 44 39 59 30
2020/2021665 14 47 72 18 169 18 65 6 86 15 120 35
2021/2022949 100 108 10 24 137 11 122 35 85 26 36 255
2022/20231.812 142 99 30 244 137 272 6 356 370 35 81 40
2023/2024831 56 144 51 40 58 266 69 111 8 28 0 0
Totale 5.687